Stams, Wendy A G <br/><br/>
Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Apr 2005 
 - 2974-80 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-04-1829  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Asparaginase--pharmacology<br/>Cell Survival--drug effects<br/>Child<br/>Chromosomes, Human, Pair 12--genetics<br/>Chromosomes, Human, Pair 21--genetics<br/>Core Binding Factor Alpha 2 Subunit<br/>DNA-Binding Proteins--genetics<br/>Disease-Free Survival<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Nuclear Proteins--genetics<br/>Oncogene Proteins, Fusion--genetics<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--genetics<br/>Prednisolone--pharmacology<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins c-ets<br/>RNA, Messenger--genetics<br/>Repressor Proteins--genetics<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Transcription Factors--genetics<br/>Translocation, Genetic<br/>Treatment Outcome<br/>Vincristine--pharmacology<br/>ETS Translocation Variant 6 Protein